IGC Pharma Inc
Company Profile
Business description
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Contact
10224 Falls Road
PotomacMD20854
USAT: +1 301 983-0998
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
67
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.80 | 86.80 | 1.00% |
| CAC 40 | 7,615.99 | 78.42 | 1.04% |
| DAX 40 | 23,644.21 | 375.20 | 1.61% |
| Dow JONES (US) | 43,011.75 | 429.97 | 1.01% |
| FTSE 100 | 8,758.99 | 0.95 | 0.01% |
| HKSE | 24,177.07 | 487.94 | 2.06% |
| NASDAQ | 19,905.30 | 274.33 | 1.40% |
| Nikkei 225 | 38,790.56 | 436.47 | 1.14% |
| NZX 50 Index | 12,467.48 | 65.17 | -0.52% |
| S&P 500 | 6,084.29 | 59.12 | 0.98% |
| S&P/ASX 200 | 8,555.50 | 80.60 | 0.95% |
| SSE Composite Index | 3,420.57 | 38.98 | 1.15% |